dr. wierda discusses trials of novel combinations in cll
Published 6 years ago • 367 plays • Length 2:19Download video MP4
Download video MP3
Similar videos
-
1:15
dr. wierda discusses sequencing new agents in cll
-
1:25
dr. wierda discusses the role of ibrutinib in cll
-
2:07
dr. wierda on factors to consider in frontline management of cll
-
1:16
dr. wierda on ibrutinib plus venetoclax in cll
-
1:13
dr. wierda discusses the need for newer therapies in cll
-
1:42
dr. wierda on combination regimens with venetoclax in cll
-
2:57
dr william wierda discusses cll phase 3 trial data as presented at ash
-
1:37
dr. wierda on using cd19-targeted car t cells in cll
-
7:45
early trial of sonrotoclax to treat chronic lymphocytic leukemia (cll) - ash 2023 dr. mazyar shadman
-
6:39
ibrutinib venetoclax for chronic lymphocytic leukemia (cll) treatment - dr. bill wierda ash 2022
-
8:19
when to initiate therapy for chronic lymphocytic leukemia
-
1:23
dr. wierda on the ascend trial and btk inhibitor-based therapies in cll
-
4:58
novel approaches to treating relapsed/refractory cll
-
1:57
dr. wierda on chemoimmunotherapy in cll
-
7:01
novel frontline combinations with ibrutinib in cll
-
1:29
dr. wierda on novel therapies in relapsed/refractory cll
-
24:17
combination of novel agents in cll: is this the final answer?
-
0:45
dr. wierda discusses watchful waiting in cll
-
1:26
dr. wierda discusses use of car t cells in cll
-
1:10
dr. wierda on frontline management of patients with cll
-
1:39
dr. wierda on role of rituximab biosimilar in evolving cll treatment paradigm
-
1:57
how genomic testing is used in the prognostication and diagnosis of patients with cll